Cleantech Co. Showcases Revolutionary Water Treatment

1. BioLargo Inc. is a billboard sponsor of Streetwise Reports and pays SWR a monthly sponsorship fee between US$4,000 and US$5,000.
2. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of BioLargo Inc.
3. Steve Sobek wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
4. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 

For additional disclosures, please click here.

Clean technology company BioLargo Inc. (BLGO:OTCQX) announced that it will present data on its industry-leading PFAS capture and destruction solution at the Air & Waste Management Association's "The Science of PFAS" conference on March 12.

The company's Aqueous Electrostatic Concentrator (AEC) technology removes more than 99% of per- and polyfluoroalkyl substances (PFAS), also known as "forever chemicals," from water, the company has said.

BioLargo will present data demonstrating AEC's removal and destruction of PFAS from landfill leachate, or the contaminant-laden water that drains from landfills.

"We're honored to be invited to present alongside a distinguished group of leaders in environmental stewardship and implementation of advanced water and air technologies at A&WMA's The Science of PFAS conference, including representatives from the U.S. Environmental Protection Agency and other federal agencies," said Tonya Chandler, president of the BioLargo subsidiary BioLargo Equipment Solutions & Technologies Inc. "Our leachate PFAS treatment results are sure to leave a strong impression with this audience."

The A&WMA was founded more than 100 years ago and is the United States' oldest environmental organization, dedicated to advancing knowledge and expertise in environmental management for more than 5,000 environmental professionals across 65 countries.

It said its "The Science of PFAS" conference in Raleigh, N.C., will "bring together scientists, researchers, academics, practitioners, regulators, and the regulated community to further the conversation on the current state of PFAS science and solutions for the future."

Process Removes Chemicals to Level of 'Non-Detection'

Last year, BioLargo's water treatment technologies secured its first commercial PFAS-treatment project, which will be ready for delivery in early 2025.

"Our team at BioLargo Equipment Solutions & Technologies is highly encouraged by the pending completion of the first installation and believes that project will springboard additional customers, which we hope will solidify our technology as a leader in economical, low-waste treatment of water contaminated with these ‘forever chemicals,'" said President and Chief Executive Officer Dennis P. Calvert.

Richard Ryan wrote for Oak Ridge Financial noted in a recent research note that "the pipeline of opportunities is large and growing" for BioLargo's AEC.

Chris Temple of The National Investor wrote on January 7 that the process of getting Clyra's production lines capable of "cranking out 1 million product units at inception" is about complete, and "Q1 will see things crank up."

"The large emerging market for PFAS removal and BLGO's growing validation in this opportunity should not be overlooked," the analyst wrote, rating the stock a Buy with a base case target price of US$0.38 per share.

"Modeling expectations are difficult to time, but we endeavored to incrementally include PFAS-related revenues and developed a bull case Price Target of $0.50."

The EPA finalized its standards on PFAS last year and classified two of the widely used ones as hazardous substances under the Superfund. First made in the 1930s, they are now found "widely in the food and water supply and in most people's blood," NPR reported.

High concentrations of some PFAS may lead to adverse health risks such as cancer, hormonal disruption, and reduced immune system effectiveness, although research is still being conducted. They are called "forever chemicals" because they break down very slowly. Tens of millions of people have been exposed.

BioLargo's AEC technology has been shown in pilot studies to meet the EPA's tough new specifications for PFAS in drinking water, the company said. The process separates the compounds in an electrostatic field, forcing them across a proprietary membrane system. The AEC's energy costs are very low, and its waste stream is a fraction of that of traditional carbon or ion exchange systems.

Testing has shown the technology removes the chemicals to a level of "non-detection," or a level at which science can no longer detect them, the company said.

The BioLargo Family of Companies

BioLargo is made up of subsidiaries that work in different sectors, a "family of companies," including ONM Environmental, BioLargo Engineering, BioLargo Water, BioLargo Energy Technologies, Clyra Medical Technologies, and the new BioLargo Equipment Solutions & Technologies Inc. (BEST) subsidiary.

ONM Environmental includes Pooph, the company's wildly successful consumer pet odor line; Clyra Medical Technologies includes its copper-iodine wound irrigation solution, Bioclynse; and BioLargo Energy has developed a new long-lasting battery that the company said is safer than lithium-ion batteries.

"Pooph was not our only success in 2024, as great strides were also made in our medical, equipment and energy divisions," Calvert said said earlier this year. "In medical, our subsidiary Clyra Medical focused its efforts on preparation of its Bioclynse wound irrigation solution for launch for surgical applications, spending countless hours and more than US$2 million readying the product for at-scale manufacturing at an FDA-compliant manufacturing partner."

Some advantages of Bioclynse include that its copper and iodine technology is non-cytotoxic, non-sensitizing, and does not damage tissue. It is non-staining with no rinse-out required, effective against biofilms, and has sustained efficacy for multiple days.

Chris Temple of The National Investor wrote on January 7 that the process of getting Clyra's production lines capable of "cranking out 1 million product units at inception" is about complete, and "Q1 will see things crank up."

"BioLargo is yet another of our story 'story stocks' you should be doubling down on at current prices," Temple wrote.

Ownership and Share Structure

About 14.6% of BioLargo is owned by insiders and management, according to Yahoo! Finance. They include Chief Science Officer Kenneth Code with 8.34%, CEO Calvert with 3.27%, and Director Jack Strommen with 1.62%, Reuters reported.

About 0.04% is held by the institution First American Trust, Reuters said.

The rest, about 85%, is retail.

Its market cap is US$76.78 million, with about 301.18 million shares outstanding and about 258.99 million free-floating. It trades in a 52-week range of US$0.38 and US$0.16.